Double-stranded RNA in neuronal cell death in alzheimer's and related neurodegenerative diseases

Active Grant Awarded Last action

Award ID
R01AG085307
Recipient
Awarding agency
Obligated
$2,306,802

Award facts

Assistance listing
93.866 Aging Research
Completion date 51% complete
Place of performance
Boulder, CO 80309, USA

Award details come from USAspending.gov.

Description

Abstract
Alzheimer's disease (ad) and related neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are characterized by neuroinflammation and neuronal cell death. Also associated with these diseases is an abnormal deposition of the TDP-43 protein. This protein has multiple roles in RNA metabolism, and we have previously demonstrated that one of its functions is to limit the accumulation of double-stranded RNA (DSRNA). DSRNA rarely accumulates in normal cells (particularly in the cytoplasm), but commonly occurs during viral infection. Thus, abnormal DSRNA is recognized by cells as a sign of infection, leading to the induction of an antiviral innate immune response and the induction of cell death pathways. The central hypothesis we will test in this proposal is that in ad and ALS/FTD the accumulation of DSRNA induces inappropriate activation of antiviral responses that contribute to the observed neuropathology. Our goals are to determine: 1) the underlying molecular mechanisms that lead to DSRNA accumulation, and 2) how DSRNA accumulation leads to glial and neuronal dysfunction. Characterization of pathways that LIE both upstream and downstream of DSRNA accumulation in the context of ad, ALS/FTD, and other neurodegenerative diseases has the potential to generate novel therapeutic targets for these currently untreatable pathologies. Our preliminary studies demonstrate that DSRNA accumulates in the hippocampus of alzheimer's patients and the motor cortex of ALS patients. We will immunopurify and sequence this DSRNA from human brain to determine its origins. Transgenic mouse models with conditional depletion of TDP-43 will be characterized to define the temporal relationships between TDP-43 loss, DSRNA accumulation, gliosis, and neuronal cell death. Infection of human ipsc-derived neural cultures with engineered lentivirus and infection of mouse models with engineered adenovirus will be used to artificially generate DSRNA to investigate the pathways by which DSRNA leads to disease-relevant neuropathology.

Transactions

Action Obligated Date
Amendment $776,876
Amendment $62,121
Amendment $698,874
Amendment $53,978
Original award $714,953

Subawards

Subrecipient Amount Awarded
Mayo Clinic Jacksonville (A Nonprofit Corporation) I. Background Information Abnormal cytoplasmic deposition and nuclear depletion of TDP-43 is observed in most patients with amyotrophic lateral sclerosis (ALS),… $212,787
Mayo Clinic Jacksonville (A Nonprofit Corporation) Statement of Work Project Title: Double-stranded RNA in neuronal cell death in Alzheimer’s and related neurodegenerative diseases Sponsor: National Institutes… $8,616
Mayo Clinic Jacksonville (A Nonprofit Corporation) $199,915
Mayo Clinic Jacksonville (A Nonprofit Corporation) I. Background Information Abnormal cytoplasmic deposition and nuclear depletion of TDP-43 is observed in most patients with amyotrophic lateral sclerosis (ALS),… $175,101

Quick answers

Who received award R01AG085307?

R01AG085307 was awarded to The Regents Of The University Of Colorado by National Institute on Aging (National Institutes of Health) on June 20, 2024.

How much is award R01AG085307 worth?

$2,306,802 has been obligated on R01AG085307.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award